This reduction in platelet activation lessens platelet‐facilitated immunosuppression and diminishes the transferred‐PD‐L1 expression from cancer cells to platelets, thus enhancing the immune response of anti‐PD‐L1 therapy. This evidence concerns the gene CD274 and cancer.